IDMet (RaDiCo Cohort) (RaDiCo-IDMet)

Launched by INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, FRANCE · Jul 6, 2023

Keywords

ClinConnect Summary

The IDMet (RaDiCo Cohort) clinical trial is studying a group of genetic disorders known as imprinting disorders, which include conditions like Silver Russell Syndrome and Angelman Syndrome. The main goal of this study is to understand how these disorders affect metabolism—essentially how the body processes food and energy. Researchers want to find out if there are common metabolic patterns among these disorders, how they impact health, and if these patterns can help doctors classify and predict outcomes for patients. They are also exploring if there are similar treatment approaches that could be helpful for all patients with these conditions.

This trial is open to both adults and children who have been diagnosed with an imprinting disorder, regardless of how severe their condition might be. Participants will need to provide signed consent, either for themselves or through a parent or guardian if they are minors. Those who join the study can expect to undergo assessments that will help researchers gather important information about their metabolic profiles. Overall, the study aims to improve understanding and treatment of these complex disorders, and your participation could contribute to significant advancements in patient care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients (adults and children) affected with an ID regardless of the severity of the disease
• • A confirmed diagnosis of ID (based on molecular diagnosis)
• • A signed informed consent for adults or signed informed consent of parents/guardians of minors/ protected adult.
• Non-Inclusion Criteria:
• • There are no non-inclusion criteria.